Patents by Inventor Ester Fernandez-Salas

Ester Fernandez-Salas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lipophilic dye-based FRET assays for clostridial toxin activity
    Patent number: 8535941
    Abstract: Compositions useful for detecting Clostridial toxin activity comprising a cell that comprises a membrane-associated Clostridial toxin substrate comprising a first member of a fluorescence resonance energy transfer pair; and a Clostridial toxin recognition sequence including a cleavage site; and a membrane-associated second member of the FRET pair and methods useful for determining Clostridial toxin activity using such Clostridial toxin substrates.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: September 17, 2013
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Kei Roger Aoki
  • METHODS OF TREATING CANCER USING OPIOD RETARGETED ENDOPEPIDASES
    Publication number: 20130230502
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.
    Type: Application
    Filed: November 20, 2012
    Publication date: September 5, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Dean G. Stathakis, Joseph Francis, Kei Roger Aoki, Ester Fernandez-Salas
  • Degradable clostridial toxins
    Patent number: 8512992
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: August 20, 2013
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Methods of Treating Cancer Using Growth Factor Retargeted Endopeptidases
    Publication number: 20130195838
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.
    Type: Application
    Filed: August 9, 2012
    Publication date: August 1, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. JACKY, Patton E. Garay, Yanira Molina, Dean G. Stathakis, Joseph Francis, Kei Roger Aoki, Ester Fernandez-Salas, Lance E. Steward, Sanjiv Ghanshani, Terrence J. Hunt
  • Botulinum toxin screening assays
    Patent number: 8497081
    Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to a FGFR2, a FGFR3, a SV2, or any combination thereof, to a governmental or regional regulatory authority.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: July 30, 2013
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Birgitte P. S. Jacky, Patton E. Garay, Kei Roger Aoki
  • Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
    Patent number: 8460682
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: June 11, 2013
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Immuno-based retargeted endopeptidase activity assays
    Patent number: 8455203
    Abstract: The present specification discloses SNAP-25 immune response inducing compositions, methods of making ?-SNAP-25 antibodies that selectively binds to an epitope comprising a SNAP-25 having a carboxyl-terminus at the P1 residue of the BoNT/A cleavage site scissile bond, ?-SNAP-25 antibodies that selectively bind to an epitope comprising a SNAP-25 having a carboxyl-terminus at the P1 residue of the BoNT/A cleavage site scissile bond, methods of detecting retargeted endopeptidase activity, and methods of detecting neutralizing ?-re-targeted endopeptidase antibodies.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: June 4, 2013
    Assignee: Allergan, Inc.
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas
  • IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
    Publication number: 20130040368
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Application
    Filed: October 11, 2012
    Publication date: February 14, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina S. Wong, D. Dianne Hodges, Kei Roger Aoki
  • Cells useful for immuno-based Botulinum toxin serotype A activity assays
    Patent number: 8361789
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: January 29, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Ester Fernandez-Salas
  • Activatable clostridial toxins
    Patent number: 8273358
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: September 25, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
  • Multivalent clostridial toxins
    Patent number: 8273865
    Abstract: The present invention is directed to multivalent Clostridial toxin comprising more than one binding domain directed to a cell surface molecule of a target cell. Such modified toxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions may be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: September 25, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • LIPOPHILIC DYE-BASED FRET ASSAYS FOR CLOSTRIDIAL TOXIN ACTIVITY
    Publication number: 20120231538
    Abstract: Compositions useful for detecting Clostridial toxin activity comprising a cell that comprises a membrane-associated Clostridial toxin substrate comprising a first member of a fluorescence resonance energy transfer pair; and a Clostridial toxin recognition sequence including a cleavage site; and a membrane-associated second member of the FRET pair and methods useful for determining Clostridial toxin activity using such Clostridial toxin substrates.
    Type: Application
    Filed: February 27, 2012
    Publication date: September 13, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Kei Roger Aoki
  • Immuno-Based Botulinum Toxin Serotype A Activity Assays
    Publication number: 20120225436
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Application
    Filed: May 18, 2012
    Publication date: September 6, 2012
    Applicant: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton Garay, Lina S. Wong, D. Diane Hodges, Kei Roger Aoki
  • Botulinum toxin screening assays
    Patent number: 8257914
    Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: September 4, 2012
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Patton E. Garay, Kei Roger Aoki
  • Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
    Publication number: 20120207733
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer or a disease of hyperproliferation in a mammal using such TVEMP compositions.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 16, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Joseph Francis, Lance E. Steward, Sanjiv Ghanshani, Terrence J. Hunt, Kei Roger Aoki, Ester Fernandez-Salas
  • Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
    Publication number: 20120207743
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal using such TVEMP compositions.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 16, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Joseph Francis, Lance E. Steward, Sanjiv Ghanshani, Terrence J. Hunt, Kei Roger Aoki, Ester Fernandez-Salas
  • Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases
    Publication number: 20120207734
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal using such TVEMP compositions.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 16, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Joseph Francis, Lance E. Steward, Sanjiv Ghanshani, Terrence J. Hunt, Kei Roger Aoki, Ester Fernandez-Salas
  • Treatments Using PSMA Ligand Endopeptidases
    Publication number: 20120207742
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a prostate cancer, a benign prostatic hyperplasia, and/or neovascularization or pathological angiogenesis associated with a cancer in a mammal using such TVEMP compositions.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 16, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Joseph Francis, Lance E. Steward, Sanjiv Ghanshani, Terrence J. Hunt, George Sachs, Kei Roger Aoki, Ester Fernandez-Salas
  • Inhibiting Aberrant Blood Vessel Formation Using Growth Factor Retargeted Endopeptidases
    Publication number: 20120207704
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal using such TVEMP compositions.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 16, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Joseph Francis, Lance E. Steward, Sanjiv Ghanshani, Terrence J. Hunt, Kei Roger Aoki, Ester Fernandez-Salas
  • Modified Clostridial Toxins with Enhanced Targeting Capabilities For Endogenous Clostridial Toxin Receptor Systems
    Publication number: 20120178140
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: February 27, 2012
    Publication date: July 12, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki